Rockwell Medical, Inc. (RMTI)
NASDAQ: RMTI · IEX Real-Time Price · USD
+0.025 (1.19%)
At close: Jul 12, 2024, 4:00 PM
-0.110 (-5.16%)
After-hours: Jul 12, 2024, 7:00 PM EDT

Company Description

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide.

Also, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers.

The company’s hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream.

The company serves to hemodialysis clinics. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012.

Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Rockwell Medical, Inc.
Rockwell Medical logo
Country United States
Founded 1994
IPO Date Jan 27, 1998
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 237
CEO Dr. Mark Strobeck Ph.D.

Contact Details

30142 Wixom Road
Wixom, Michigan 48393
United States
Phone (800) 449-3353

Stock Details

Ticker Symbol RMTI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001041024
CUSIP Number 774374300
ISIN Number US7743743004
Employer ID 38-3317208
SIC Code 2834

Key Executives

Name Position
Dr. Mark Strobeck Ph.D. President, Chief Executive Officer and Director
Megan C. Timmins Executive Vice President, Chief Legal Officer and Secretary
Jesse Neri Senior Vice President of Finance
James A. McCarthy Senior Vice President of Business and Corporate Development
Timothy T. Chole Senior Vice President of Sales and Marketing
Heather R. Hunter Senior Vice President and Chief Corporate Affairs Officer
David J. Kull Secretary
Jason Finkelstein Investor Relations Representative

Latest SEC Filings

Date Type Title
Jul 1, 2024 SCHEDULE 13G/A Filing
Jun 25, 2024 SCHEDULE 13G/A Filing
Jun 13, 2024 SCHEDULE 13G/A Filing
May 30, 2024 SCHEDULE 13G/A Filing
May 30, 2024 SCHEDULE 13G/A Filing
May 23, 2024 8-K Current Report
May 14, 2024 8-K Current Report
May 14, 2024 10-Q Quarterly Report
May 14, 2024 8-K Current Report
May 3, 2024 SCHEDULE 13G Filing